Mini Review on Polymer-based Nano Enable System for Targeted Delivery
of Chalcone Derivatives against Cancerous Tissues: An Effective Treatment
Approach

Swarupananda      Mukherjee; Dipanjan      Karati

doi:10.2174/2452271606666230731103057

Abstract

Nanotechnology augmentation have enabled the creation of innovative colloidal preparations that can modify the pharmacological characteristics of medications. Numerous effective applications in the treatment of cancer have been made possible by the distinctive physicochemical and technological characteristics of therapies based on nanomaterials. To facilitate and maximize the interaction between cells and tissues, it is necessary to examine and modify the size, shape, charge, and patterning of nanoscale therapeutic molecules. The flavonoids chalcones and their natural scaffolds provide a variety of biological effects crucial for creating medicines. Plant-based anticancer medicines represent a promising scientific and business opportunity that should be investigated. By using traditional Chinese medicine (TCM) therapies, diseases can be avoided, and healthcare can be enhanced. Traditional Chinese medicine is safe, straightforward, and reasonably priced. There are numerous treatments for chronic, geriatric, and incurable diseases. Heterocyclic equivalents of chalcones have a variety of biological properties. One of them is its anti-cancer properties, and as a result Chalcones have drawn a huge interest in the study of malignancy. Licorice is an essential primary ingredient in many traditional folk medicines, including Chinese and Mongolian medicine. Research on chalcone scaffolds with strong growth-inhibitory activity in tumor cell lines was influenced by the rising interest in this medicinal molecule, and numerous papers on these scaffolds are now accessible. It is necessary to do a thorough examination before chalcone congeners can be developed as a prodrug or primary chemical to treat cancer. To create a focused and efficient drug delivery system for cancer treatment, we shall discuss chalcone derivatives and their nano-enabled drug delivery systems in this article. It has been discussed how polymeric nanoparticles might effectively localize in particular tumor tissues and act as drug delivery vehicles for anticancer drugs due to their physicochemical characteristics. A promising strategy to increase the effectiveness of various tumor treatments is the nanoencapsulation of anticancer active substances in polymeric systems.

« Previous Next »

Graphical Abstract

[1]
Chivere VT, Kondiah PPD, Choonara YE, Pillay V. Nanotechnology-based biopolymeric oral delivery platforms for advanced cancer treatment. Cancers  2020; 12(2): 522.
 [http://dx.doi.org/10.3390/cancers12020522] [PMID:  32102429]

[2]
Cancer Facts and Statistics  Available From :    http://www.cancer.org/acs/groups/content/@research/documents/webcontent/acspc-041787.pdf
          [Accessed on: Jan 5, 2015
      

[3]
Mahapatra DK, Bharti SK, Asati V. AntiChalco-cancer nes:	Structural and molecular target perspectives. Eur J Med Chem  2015; 5234(15): 0223-3003.

[4]
Gordaliza M. Natural products as leads to anticancer drugs. Clin Transl Oncol  2007; 9(12): 767-76.
 [http://dx.doi.org/10.1007/s12094-007-0138-9] [PMID:  18158980]

[5]
Breast Cancer Facts & Figures http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-042725.pdf

[6]
Dhaini B, Daouk J. Rose bengal coupled to aguix nps for anti-cancer photodynamic therapy. Photodiagnosis Photodyn Ther  2023; 41: 103424.
 [http://dx.doi.org/10.1016/j.pdpdt.2023.103424]

[7]
Dhaini B, Wagner L, Moinard M, et al. Importance of rose bengal loaded with nanoparticles for anti-cancer photodynamic therapy. Pharmaceuticals  2022; 15(9): 1093.
 [http://dx.doi.org/10.3390/ph15091093] [PMID:  36145315]

[8]
Dhaini B, Kenzhebayeva B, Ben-Mihoub A, et al. Peptide-conjugated nanoparticles for targeted photodynamic therapy. Nanophotonics  2021; 10(12): 3089-134.
 [http://dx.doi.org/10.1515/nanoph-2021-0275]

[9]
Al Dine JE. A facile approach for the doxorubicine delivery in cancer cells by responsive and fluorescent core/shell quantum dots. Bioconjug Chem  2018; 29(7): 2248-56.

[10]
Youssef Z, Jouan-Hureaux V, Colombeau L, et al. Titania and silica nanoparticles coupled to Chlorin e6 for anti-cancer photodynamic therapy. Photodiagn Photodyn Ther  2018; 22: 115-26.
 [http://dx.doi.org/10.1016/j.pdpdt.2018.03.005] [PMID:  29581041]

[11]
Youssef Z. The application of titanium dioxide, zinc oxide, fullerene, and graphene nanoparticles in photodynamic therapy. Cancer Nanotechnol  2017; 5(6): 1-62.

[12]
Jamal Al Dine E. Synthesis and characterization of smart nanomaterials for cancer treatment.  9th International Conference on Material Sciences (CSM9). August 26-28, 2015; ENSIC,	Nancy, France. 2015.

[13]
Youssef Z, Arnoux P, Colombeau L, et al. Two approaches for elaborating sensitized TiO 2 nanoparticles of potential effect in photodynamic therapy. Photodiagn Photodyn Ther  2017; 17: A61-2.
 [http://dx.doi.org/10.1016/j.pdpdt.2017.01.138]

[14]
Ouyang Y, Li J, Chen X, Fu X, Sun S, Wu Q. Chalcone derivatives: Role in anticancer therapy. Biomolecules  2021; 11(6): 894.
 [http://dx.doi.org/10.3390/biom11060894] [PMID:  34208562]

[15]
Ahmed MF, Santali EY, El-Haggar R. Novel piperazine–chalcone hybrids and related pyrazoline analogues targeting VEGFR-2 kinase; design, synthesis, molecular docking studies, and anticancer evaluation. J Enzyme Inhib Med Chem  2021; 36(1): 308-19.
 [http://dx.doi.org/10.1080/14756366.2020.1861606] [PMID:  33349069]

[16]
Abosalim HM, Nael MA, El-Moselhy TF. Design, synthesis and molecular docking of chalcone derivatives as potential anticancer agents. ChemistrySelect  2021; 6(4): 888-95.
 [http://dx.doi.org/10.1002/slct.202004088]

[17]
Ngameni B, Cedric K, Mbaveng AT, et al. Design, synthesis, characterization, and anticancer activity of a novel series of O-substituted chalcone derivatives. Bioorg Med Chem Lett  2021; 35: 127827.
 [http://dx.doi.org/10.1016/j.bmcl.2021.127827] [PMID:  33508467]

[18]
Ahn S, Truong VNP, Kim B, et al. Design, synthesis, and biological evaluation of chalcones for anticancer properties targeting glycogen synthase kinase 3 beta. Applied Biological Chemistry  2022; 65(1): 17.
 [http://dx.doi.org/10.1186/s13765-022-00686-x]

[19]
Shin SY, Jung E, Lim Y, et al. Synthesis, crystal structure, hirshfeld surface analysis and docking studies of a novel flavone–chalcone hybrid compound demonstrating anticancer effects by generating ros through glutathione depletion. Crystals  2022; 12(1): 108.
 [http://dx.doi.org/10.3390/cryst12010108]

[20]
Li K, Zhao S, Long J, et al. A novel chalcone derivative has antitumor activity in melanoma by inducing DNA damage through the upregulation of ROS products. Cancer Cell Int  2020; 20(1): 36.
 [http://dx.doi.org/10.1186/s12935-020-1114-5] [PMID:  32021565]

[21]
Medina O, Zhu Y, Kairemo K. Targeted liposomal drug delivery in cancer. Curr Pharm Des  2005; 10(24): 2981-9.
 [http://dx.doi.org/10.2174/1381612043383467]

[22]
Khare S, Alexander A, Ajazuddi AN. Biomedical applications of nanobiotechnology for drug design, delivery and diagnostics. In: Res. J Pharm Technol  2014; 7(8)

[23]
Ajazuddin SS. Applications of novel drug delivery system for herbal formulations. Fitoterapia  2010; 81(7): 680-9.
 [http://dx.doi.org/10.1016/j.fitote.2010.05.001]

[24]
Alexander A. Ajazuddin, Patel RJ, Saraf S, Saraf S. Recent expansion of pharmaceutical nanotechnologies and targeting strategies in the field of phytopharmaceuticals for the delivery of herbal extracts and bioactives. J Control Release  2016; 241: 110-24.
 [http://dx.doi.org/10.1016/j.jconrel.2016.09.017] [PMID:  27663228]

[25]
Jacob S, Nair AB, Shah J. Emerging role of nanosuspensions in drug delivery systems. Biomater Res  2020; 24(1): 3.
 [http://dx.doi.org/10.1186/s40824-020-0184-8] [PMID:  31969986]

[26]
Salari N, Faraji F, Torghabeh FM, et al. Polymer-based drug delivery systems for anticancer drugs: A systematic review. Cancer Treat Res Commun  2022; 32: 100605.
 [http://dx.doi.org/10.1016/j.ctarc.2022.100605] [PMID:  35816909]

[27]
Patravale VB, Date AA, Kulkarni RM. Nanosuspensions: A promising drug delivery strategy. J Pharm Pharmacol  2010; 56(7): 827-40.
 [http://dx.doi.org/10.1211/0022357023691] [PMID:  15233860]

[28]
Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev  2000; 45(1): 89-121.
 [http://dx.doi.org/10.1016/S0169-409X(00)00103-4] [PMID:  11104900]

[29]
Gagliardi A, Giuliano E, Venkateswararao E, et al. Biodegradable polymeric nanoparticles for drug delivery to solid tumors. Front Pharmacol  2021; 12: 601626.
 [http://dx.doi.org/10.3389/fphar.2021.601626] [PMID:  33613290]

[30]
Rehman AU, Akram S, Seralin A, Vandamme T, Anton N. Lipid nanocarriers: Formulation, properties, and applications.In:Smart Nanocontainers.  Amsterdam, The Netherlands: Elsevier 2020; pp. 355-82.
 [http://dx.doi.org/10.1016/B978-0-12-816770-0.00021-6]

[31]
Asasutjarit R, Managit C, Phanaksri T, Treesuppharat W, Fuongfuchat A. Formulation development and in vitro evaluation of transferrin-conjugated liposomes as a carrier of ganciclovir targeting the retina. Int J Pharm  2020; 577: 119084.
 [http://dx.doi.org/10.1016/j.ijpharm.2020.119084] [PMID:  31988033]

[32]
Temidayo OB, Olusanya Rita Rushdi Haj Ahmad. Liposomal drug delivery systems and anticancer drugs. Molecules  2018; 23: 907.

[33]
Ge X, Wei M, He S, Yuan WE. Advances of non-ionic surfactant vesicles (niosomes) and their application in drug delivery. Pharmaceutics  2019; 11(2): 55.
 [http://dx.doi.org/10.3390/pharmaceutics11020055] [PMID:  30700021]

[34]
Grimaudo MA, Pescina S, Padula C, et al. Poloxamer 407/TPGS Mixed micelles as promising carriers for cyclosporine ocular delivery. Mol Pharm  2018; 15: 571-84.

[35]
Bisht S, Feldmann G, Soni S, et al. Polymeric nanoparticle-encapsulated curcumin (“nanocurcumin”): A novel strategy for human cancer therapy. J Nanobiotechnol  2007; 5(1): 3.
 [http://dx.doi.org/10.1186/1477-3155-5-3] [PMID:  17439648]

[36]
Wang F, Bao X, Fang A, et al. Nanoliposome-encapsulated brinzolamide-hydropropyl-beta-cyclodextrin inclusion complex: A potential therapeutic ocular drug-delivery system. Front Pharmacol  2018; 9: 91.
 [http://dx.doi.org/10.3389/fphar.2018.00091] [PMID:  29487529]

[37]
Chakraborty M, Banerjee D, Mukherjee S, Karati D. Exploring the advancement of polymer-based nano-formulations for ocular drug delivery systems: An explicative review. Polym Bull 2022.
 [http://dx.doi.org/10.1007/s00289-022-04661-w]

[38]
Singh R, Lillard JW Jr. Nanoparticle-based targeted drug delivery. Exp Mol Pathol  2009; 86(3): 215-23.
 [http://dx.doi.org/10.1016/j.yexmp.2008.12.004] [PMID:  19186176]

[39]
Ahmed F, Pakunlu RI, Srinivas G, et al. Shrinkage of a rapidly growing tumor by drug-loaded polymersomes: PH-triggered release through copolymer degradation. Mol Pharm  2006; 3(3): 340-50.
 [http://dx.doi.org/10.1021/mp050103u] [PMID:  16749866]

[40]
Karati D. A concise review on bio-responsive polymers in targeted drug delivery system. Polym Bull  2022; 80(4)
 [http://dx.doi.org/10.1007/s00289-022-04424-7]

[41]
Quader S, Van Guyse JFR. Bioresponsive polymers for nanomedicine—expectations and reality! Polymers  2022; 14(17): 3659.
 [http://dx.doi.org/10.3390/polym14173659] [PMID:  36080733]

[42]
Chu S, Shi X, Tian Y, Gao F. pH-Responsive polymer nanomaterials for tumor therapy. Front Oncol  2022; 12: 855019.
 [http://dx.doi.org/10.3389/fonc.2022.855019] [PMID:  35392227]

[43]
Brasseur K, Gévry N, Asselin E. Chemoresistance and targeted therapies in ovarian and endometrial cancers. Oncotarget  2017; 8(3): 4008-42.
 [http://dx.doi.org/10.18632/oncotarget.14021] [PMID:  28008141]

[44]
Patel A, Sant S. Hypoxic tumor microenvironment: Opportunities to develop targeted therapies. Biotechnol Adv  2016; 34(5): 803-12.
 [http://dx.doi.org/10.1016/j.biotechadv.2016.04.005] [PMID:  27143654]

[45]
Liu J, Chen Q, Feng L, Liu Z. Nanomedicine for tumor microenvironment modulation and cancer treatment enhancement. Nano Today  2018; 21: 55-73.
 [http://dx.doi.org/10.1016/j.nantod.2018.06.008]

[46]
Estrella V, Chen T, Lloyd M, et al. Acidity generated by the tumor microenvironment drives local invasion. Cancer Res  2013; 73(5): 1524-35.
 [http://dx.doi.org/10.1158/0008-5472.CAN-12-2796] [PMID:  23288510]

[47]
Li X, Li H, Zhang ZY. Research progress of stimuli-responsive polymers in tumor immunotherapy. Prog Pharm Sci  2021; 45(5): 325-36.

[48]
Manchun S, Dass CR, Sriamornsak P. Targeted therapy for cancer using pH-responsive nanocarrier systems. Life Sci  2012; 90(11-12): 381-7.
 [http://dx.doi.org/10.1016/j.lfs.2012.01.008] [PMID:  22326503]

[49]
McMahon HT, Boucrot E. Molecular mechanism and physiological functions of clathrin-mediated endocytosis. Nat Rev Mol Cell Biol  2011; 12(8): 517-33.
 [http://dx.doi.org/10.1038/nrm3151] [PMID:  21779028]

[50]
Qiu L, Qiao M, Chen Q, et al. Enhanced effect of pH-sensitive mixed copolymer micelles for overcoming multidrug resistance of doxorubicin. Biomaterials  2014; 35(37): 9877-87.
 [http://dx.doi.org/10.1016/j.biomaterials.2014.08.008] [PMID:  25201738]

[51]
Liu FH, Cong Y, Qi GB, Ji L, Qiao ZY, Wang H. Near-infrared laser-driven in situ self-assembly as a general strategy for deep tumor therapy. Nano Lett  2018; 18(10): 6577-84.
 [http://dx.doi.org/10.1021/acs.nanolett.8b03174] [PMID:  30251542]

[52]
Alsehli M. Polymeric nanocarriers as stimuli-responsive systems for targeted tumor (cancer) therapy: Recent advances in drug delivery. Saudi Pharm J  2020; 28(3): 255-65.
 [http://dx.doi.org/10.1016/j.jsps.2020.01.004] [PMID:  32194326]

[53]
Ramırez-Garc ıa PD, Retamal JS, Shenoy P, Imlach W, Sykes M, Truong N. A pH-Responsive nanoparticle targets the neurokinin 1 receptor in endosomes to prevent chronic pain. Nat Nanotechnol  2019; 14(12): 1150-9.

[54]
Wang J, Byrne JD, Napier ME, DeSimone JM. More effective nanomedicines through particle design. Small  2011; 7(14): 1919-31.
 [http://dx.doi.org/10.1002/smll.201100442] [PMID:  21695781]

[55]
Matos MJ, Vazquez-Rodriguez S, Uriarte E, Santana L. Potential pharmacological uses of chalcones: A patent review (from June 2011 – 2014). Expert Opin Ther Pat  2015; 25(3): 351-66.
 [http://dx.doi.org/10.1517/13543776.2014.995627] [PMID:  25598152]

[56]
Lin CT, Senthil Kumar KJ, Tseng YH, et al. Anti-inflammatory activity of flavokawain b from alpinia pricei hayata. J Agric Food Chem  2009; 57(14): 6060-5.
 [http://dx.doi.org/10.1021/jf900517d] [PMID:  19537711]

[57]
Lin Y, Kuang Y, Li K, et al. Screening for bioactive natural products from a 67-compound library of Glycyrrhiza inflata. Bioorg Med Chem  2017; 25(14): 3706-13.
 [http://dx.doi.org/10.1016/j.bmc.2017.05.009] [PMID:  28522265]

[58]
Franceschelli S, Pesce M, Vinciguerra I, et al. Licocalchone-c extracted from glycyrrhiza glabra inhibits lipopolysaccharide-interferon-γ inflammation by improving antioxidant conditions and regulating inducible nitric oxide synthase expression. Molecules  2011; 16(7): 5720-34.
 [http://dx.doi.org/10.3390/molecules16075720] [PMID:  21734629]

[59]
Daikonya A, Katsuki S, Kitanaka S. Antiallergic agents from natural sources 9. Inhibition of nitric oxide production by novel chalcone derivatives from Mallotus philippinensis (Euphorbiaceae). Chem Pharm Bull  2004; 52(11): 1326-9.
 [http://dx.doi.org/10.1248/cpb.52.1326] [PMID:  15516755]

[60]
Lee WL, Huang JY, Shyur LF. Phytoagents for cancer management: Regulation of nucleic acid oxidation, ROS, and related mechanisms. Oxid Med Cell Longev  2013; 2013: 1-22.
 [http://dx.doi.org/10.1155/2013/925804] [PMID:  24454991]

[61]
Yan X, Xie T, Wang S, Wang Z, Li H, Ye Z. Apigenin inhibits proliferation of human chondrosarcoma cells via cell cycle arrest and mitochondrial apoptosis induced by ROS generation-an in vitro and in vivo study. Int J Clin Exp Med  2018; 11(3): 1615-31.

[62]
Stein Y, Rotter V, Aloni-Grinstein R. Gain-of-function mutant p53: All the roads lead to tumorigenesis. Int J Mol Sci  2019; 20(24): 6197.
 [http://dx.doi.org/10.3390/ijms20246197] [PMID:  31817996]

[63]
Wu D, Prives C. Relevance of the p53–MDM2 axis to aging. Cell Death Differ  2018; 25(1): 169-79.
 [http://dx.doi.org/10.1038/cdd.2017.187] [PMID:  29192902]

[64]
Hoesel B, Schmid JA. The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer  2013; 12(1): 86.
 [http://dx.doi.org/10.1186/1476-4598-12-86] [PMID:  23915189]

[65]
Perkins ND. The diverse and complex roles of NF-κB subunits in cancer. Nat Rev Cancer  2012; 12(2): 121-32.
 [http://dx.doi.org/10.1038/nrc3204] [PMID:  22257950]

[66]
Gamble C, McIntosh K, Scott R, Ho KH, Plevin R, Paul A. Inhibitory kappa b kinases as targets for pharmacological regulation. Br J Pharmacol  2012; 165(4): 802-19.
 [http://dx.doi.org/10.1111/j.1476-5381.2011.01608.x] [PMID:  21797846]

[67]
Baldwin AS. Regulation of cell death and autophagy by IKK and NF-κB: Critical mechanisms in immune function and cancer. Immunol Rev  2012; 246(1): 327-45.
 [http://dx.doi.org/10.1111/j.1600-065X.2012.01095.x] [PMID:  22435564]

[68]
Yadav VR, Prasad S, Sung B, Aggarwal BB. The role of chalcones in suppression of NF-κB-mediated inflammation and cancer. Int Immunopharmacol  2011; 11(3): 295-309.
 [http://dx.doi.org/10.1016/j.intimp.2010.12.006] [PMID:  21184860]

[69]
Pandey MK, Sandur SK, Sung B, Sethi G, Kunnumakkara AB, Aggarwal BB. Butein, a tetrahydroxychalcone, inhibits nuclear factor (NF)-kappaB and NF-kappaB-regulated gene expression through direct inhibition of IkappaBalpha kinase beta on cysteine 179 residue. J Biol Chem  2007; 282(24): 17340-50.
 [http://dx.doi.org/10.1074/jbc.M700890200] [PMID:  17439942]

[70]
Ducki S, Rennison D, Woo M, et al. Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: Synthesis and biological evaluation of antivascular activity. Bioorg Med Chem  2009; 17(22): 7698-710.
 [http://dx.doi.org/10.1016/j.bmc.2009.09.039] [PMID:  19837593]

[71]
Ducki S, Mackenzie G, Greedy B, et al. Combretastatin-like chalcones as inhibitors of microtubule polymerisation. Part 2: Structure-based discovery of alpha-aryl chalcones. Bioorg Med Chem  2009; 17(22): 7711-22.
 [http://dx.doi.org/10.1016/j.bmc.2009.09.044] [PMID:  19837594]

[72]
Mirossay L, Varinská L, Mojžiš J. Antiangiogenic effect of flavonoids and chalcones: An update. Int J Mol Sci  2017; 19(1): 27.
 [http://dx.doi.org/10.3390/ijms19010027] [PMID:  29271940]

[73]
Cerezo AB, Winterbone MS, Moyle CWA, Needs PW, Kroon PA. Molecular structure‐function relationship of dietary polyphenols for inhibiting VEGF‐induced VEGFR‐2 activity. Mol Nutr Food Res  2015; 59(11): 2119-31.
 [http://dx.doi.org/10.1002/mnfr.201500407] [PMID:  26250940]

[74]
Shanmugam MK, Warrier S, Kumar AP, Sethi G, Arfuso F. Potential role of natural compounds as anti-angiogenic agents in cancer. Curr Vasc Pharmacol  2017; 15(6): 503-19.
 [PMID:  28707601]

[75]
Ma Y, Xu B, Yu J, et al. Fli-1 Activation through targeted promoter activity regulation using a novel 3′,5′-diprenylated chalcone inhibits growth and metastasis of prostate cancer cells. Int J Mol Sci  2020; 21(6): 2216.
 [http://dx.doi.org/10.3390/ijms21062216] [PMID:  32210104]

[76]
Iheagwam FN, Ogunlana OO, Ogunlana OE, Isewon I, Oyelade J. Potential anti-cancer flavonoids isolated from caesalpinia bonduc young twigs and leaves: Molecular docking and in silico studies. Bioinform Biol Insights  2019; 13.
 [http://dx.doi.org/10.1177/1177932218821371] [PMID:  30670919]

[77]
Imidazolone-chalcone derivatives as potential anticancer agent and process for the preparation thereof. Patent WO2011086412A3, 2012.

[78]
Coumarin-chalcones as anticancer agents. Patent US8815940B2, 2012.

[79]
Vinylogous chalcone derivatives and their medical use. 2012.Patent CA2806006A1,  O2012013

[80]
Arizona biomedical research commission assignee. modified chalcone compounds as antimitotic agents. 2013; 8552066.

[81]
Gloria L, Abdul-Raheem TK. 1-Adamantyl Chalcones for the treatment of proliferative DISORDERS. Patent US6864264B1, 2013.

[82]
 Seoul national university industry foundation seoul and industryacademic cooperation foundation, seoul, anti-cancer composition	containing chalcone compounds EP 2601943.2013; 

[83]
Chalcone compound containing piperazine ring and preparation	and application thereof  Patent CN103102332A, 2013.

[84]
Novel chalcone derivative and anticancer composition comprising same as active ingredient.  Patent WO2013054998A1, 2013.

[85]
 Chalcone oxime derivatives having inhibiting effect on cancer cell tubulin polymerization, and preparation method thereof. Patent CN103664689A, 2014.

[86]
 O-phenyl chalcone compound as well as preparation method and application thereof.  Patent CN10375573 2 A, 2014.

[87]
Bonifácio BV, Silva PB, Ramos MA, Negri KM, Bauab TM, Chorilli M. Nanotechnology-based drug delivery systems and herbal medicines: A review. Int J Nanomedic  2014; 9: 1-15.
 [PMID:  24363556]

[88]
Carriers N, Remedies H, Technology N, Sachan AK. A review on nanotized herbal drugs. Int J Pharm Sci Res  2015; 6(3): 961-70.
 [http://dx.doi.org/10.13040/IJPSR.0975-8232.6(3).961-70]

[89]
Kim YJ, Lee KP, Lee DY, et al. Anticancer activity of a new chalcone derivative-loaded polymeric micelle. Macromol Res  2019; 27(1): 48-54.
 [http://dx.doi.org/10.1007/s13233-019-7002-y]

[90]
Winter E, Pizzol C, Locatelli C, et al. In vitro and in vivo effects of free and chalcones-loaded nanoemulsions: insights and challenges in targeted cancer chemotherapies. Int J Environ Res Public Health  2014; 11(10): 10016-35.
 [http://dx.doi.org/10.3390/ijerph111010016] [PMID:  25264679]

Rights & Permissions Print Cite

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/2452271606666230731103057	Print ISSN 2452-2716
Publisher Name Bentham Science Publisher	Online ISSN 2452-2724

Current Applied Polymer Science

Mini Review on Polymer-based Nano Enable System for Targeted Delivery of Chalcone Derivatives against Cancerous Tissues: An Effective Treatment Approach

Abstract Play Pause

Graphical Abstract

Abstract